Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia
Table 4
The normalized abundance of each selected and grouped glycoform detected in each individual sample.
Selected glycoforms
Grouped glycoforms
H4N2
H5N4S2F1
H5N4S2
H5N4S1F1
H6N3S1
H5N2
Unsialylated
Monosialylated
Disialylated
Sialylated
Fucosylated
Unfucosylated
Total
RT (min)
11.5–13.3
13.0–15.5
13.5–15.2
12.8–13.8
12.0–13.0
11.1–11.6
H4N2 + H5N2
H5N3S1F1 + H5N3S1
H5N4S2F1 + H5N4S2
Monosialylated + Disialylated
H5N4S2F1 + H5N4S1F1
H4N2 + H5N4S2 + H6N3S1 + H5N2
M + 3H
720.01
1152.16
1103.47
1055.13
992.77
773.69
BPH003
4.27
1.62
2.29
3.91
4.27
8.18
5.89
2.29
8.18
BPH004
0.70
2.53
3.58
6.12
0.70
6.81
3.23
3.58
6.81
BPH005
0.13
0.60
0.38
0.50
0.88
0.73
1.61
0.51
1.10
1.61
BPH006
0.71
0.21
0.94
5.95
6.89
0.93
7.81
1.65
6.16
7.81
BPH009
0.21
0.12
0.34
0.01
0.35
0.33
0.68
0.55
0.13
0.68
BPH012
0.14
0.63
0.18
0.89
0.74
0.35
0.49
1.63
0.82
2.45
1.53
1.41
2.94
BPH015
0.07
0.62
0.17
0.50
0.31
0.05
0.12
0.81
0.79
1.59
1.12
0.59
1.71
BPH016
0.38
0.02
0.61
0.17
0.78
0.40
1.18
0.99
0.19
1.18
BPH017
0.59
0.32
0.25
1.29
1.15
0.62
1.21
2.44
0.57
3.01
1.61
2.61
4.22
BPH019
0.68
0.28
0.25
0.10
0.81
0.68
0.91
0.53
1.44
0.38
1.74
2.12
BPH020
0.23
0.55
0.78
0.78
0.23
0.55
0.78
BPH021
0.95
0.31
1.12
0.30
0.29
1.24
1.42
0.31
1.73
1.43
1.54
2.97
BPH022
0.16
0.65
0.42
0.51
0.45
0.15
0.32
0.96
1.07
2.03
1.16
1.19
2.35
BPH025
0.34
0.69
0.60
1.03
0.56
0.34
1.59
1.29
2.89
1.72
1.50
3.23
BPH029
0.53
0.30
0.07
0.48
0.68
0.52
1.05
1.15
0.38
1.53
0.78
1.79
2.58
BPH030
0.50
0.32
0.11
0.43
0.50
0.93
0.81
0.11
0.93
BPH031
0.34
0.24
0.12
0.65
0.44
0.58
0.91
1.10
0.36
1.46
0.89
1.48
2.37
BPH032
0.13
0.40
0.24
0.49
0.30
0.12
0.25
0.80
0.64
1.43
0.89
0.79
1.68
BPH033
0.04
0.06
0.04
0.07
0.07
0.11
0.04
0.14
0.10
0.11
0.21
BPH034
0.09
0.55
0.36
0.50
0.65
0.10
0.18
1.15
0.91
2.06
1.05
1.19
2.25
BPH035
0.24
0.32
0.11
0.49
0.37
0.28
0.52
0.86
0.43
1.30
0.81
1.00
1.82
BPH036
0.06
0.17
0.25
0.25
0.17
0.06
0.23
0.23
0.25
0.48
BPH037
0.35
0.33
0.08
0.34
0.37
0.29
0.63
0.71
0.41
1.12
0.66
1.09
1.75
BPH038
0.75
1.16
0.89
0.44
1.30
0.75
1.74
2.05
3.80
1.60
2.94
4.55
BPH039
0.13
1.37
0.02
0.32
0.32
1.39
0.13
1.52
1.50
0.34
1.84
BPH040
0.78
0.24
0.06
0.14
1.04
0.73
1.51
1.18
0.30
1.48
0.38
2.61
2.98
BPH042
0.52
0.14
0.66
0.66
0.52
0.14
0.66
BPH044
0.24
0.53
0.25
0.49
0.68
0.34
0.58
1.16
0.78
1.95
1.02
1.51
2.53
BPH045
0.79
6.22
2.33
2.33
7.01
9.34
0.79
8.55
9.34
BPH046
0.15
0.13
0.17
0.17
0.29
0.29
0.15
0.30
0.45
BPH047
0.10
0.41
0.35
0.49
0.58
0.10
0.21
1.07
0.76
1.83
0.90
1.13
2.03
BPH048
0.29
0.49
0.14
0.51
0.49
0.23
0.52
1.00
0.64
1.64
1.00
1.16
2.16
BPH049
0.78
0.16
0.58
0.15
0.73
0.94
1.67
1.36
0.31
1.67
BPH050
0.80
0.80
0.80
0.80
0.80
BPH051
1.91
0.96
2.09
3.06
1.91
4.96
2.87
2.09
4.96
BPH054
0.95
0.07
0.06
0.65
0.88
1.17
2.11
1.53
0.13
1.66
0.73
3.05
3.77
BPH055
0.17
0.16
0.29
0.20
0.49
0.32
0.81
0.45
0.36
0.81
BPH057
0.24
0.92
0.09
0.21
0.27
0.64
0.88
0.48
1.00
1.48
1.13
1.23
2.36
BPH058
1.31
0.65
0.07
0.09
1.23
1.18
2.49
1.32
0.72
2.04
0.74
3.79
4.53
BPH060
0.10
0.59
0.19
0.39
0.29
0.06
0.16
0.67
0.78
1.45
0.97
0.64
1.61
BPH061
0.12
0.15
0.33
0.48
0.14
0.14
0.81
0.27
1.08
0.44
0.77
1.22
BPH063
0.57
2.54
2.85
5.39
0.57
5.96
3.11
2.85
5.96
BPH068
0.44
0.11
0.61
0.17
0.08
0.08
0.78
0.54
1.32
1.05
0.35
1.40
PCa131
1.57
1.57
1.57
1.57
1.57
PCa133
0.14
0.06
0.36
0.13
0.49
0.20
0.69
0.50
0.19
0.69
PCa135
0.85
0.09
0.16
0.24
0.34
0.85
0.58
0.25
0.83
0.33
1.35
1.68
PCa137
0.40
1.04
1.04
0.40
1.44
0.40
1.04
1.44
PCa139
0.26
0.12
0.27
0.19
0.46
0.38
0.84
0.53
0.31
0.84
PCa143
0.62
0.62
0.62
0.62
0.62
PCa145
0.49
0.33
0.49
0.30
0.79
0.82
1.61
0.98
0.63
1.61
PCa152
0.65
0.09
0.46
0.59
1.05
0.74
1.79
1.10
0.68
1.79
PCa157
0.13
0.07
0.37
0.17
0.55
0.20
0.75
0.51
0.24
0.75
PCa161
0.25
0.28
0.11
0.29
0.55
0.34
0.59
0.83
0.39
1.22
0.57
1.24
1.81
PCa162
0.17
0.42
0.11
0.28
0.24
0.19
0.36
0.52
0.52
1.04
0.69
0.71
1.40
PCa165
0.47
0.42
0.42
0.47
0.47
0.89
0.89
PCa166
0.98
0.14
0.41
0.28
1.26
0.41
0.14
0.55
0.14
1.68
1.82
PCa171
0.28
0.26
0.02
0.34
0.26
0.41
0.69
0.60
0.28
0.87
0.60
0.97
1.57
PCa003
0.22
0.27
0.71
0.97
0.22
1.20
0.49
0.71
1.20
PCa012
1.99
0.09
0.38
0.47
1.99
2.45
2.07
0.38
2.45
PCa013
1.01
0.09
0.21
0.79
1.00
1.11
2.11
1.22
0.89
2.11
PCa017
0.22
0.44
0.06
0.44
0.28
0.21
0.43
0.71
0.49
1.21
0.87
0.76
1.63
PCa019
0.51
0.21
1.01
1.21
0.51
1.72
0.71
1.01
1.72
PCa025
0.11
0.18
0.64
0.82
0.11
0.93
0.29
0.64
0.93
-value
0.478
0.137
0.137
<0.001
0.043
0.637
0.513
0.004
0.122
0.006
0.054
0.003
<0.001
() The retention time (RT) of the selected reference peptide (KIDTIVANP, [M + 2H]2+ = 485.78) was 16–18 min in 30 min LC running time. () Grouped glycoforms are a combination of the level of indicated glycopeptides in each individual sample. “Total” includes all six selected glycopeptides. () Each sample was analyzed and duplicated and the average is shown. () indicates , indicates , and indicates .
